{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:28:15Z","timestamp":1794446895225,"version":"4.9.1"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41571-025-01079-x","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:35:57Z","timestamp":1759923357000},"page":"7-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Achieving control of nasopharyngeal carcinoma: the role of Epstein\u2013Barr virus-based screening and vaccines"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-5609","authenticated-orcid":false,"given":"W. K. Jacky","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-1102","authenticated-orcid":false,"given":"Brigette B. Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasine","family":"Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C. Allen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8091","authenticated-orcid":false,"given":"Anthony T. C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"1079_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong, K. C. W. et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat. Rev. Clin. Oncol. 18, 679\u2013695 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1079_CR2","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-06-0353","volume":"15","author":"ET Chang","year":"2006","unstructured":"Chang, E. T. & Adami, H. O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomark. Prev. 15, 1765\u20131777 (2006).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1079_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young, L. S., Yap, L. F. & Murray, P. G. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789\u2013802 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1079_CR4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/2281056a0","volume":"228","author":"H zur Hausen","year":"1970","unstructured":"zur Hausen, H. et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056\u20131058 (1970).","journal-title":"Nature"},{"key":"1079_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1116143","volume":"14","author":"ZY Su","year":"2023","unstructured":"Su, Z. Y., Siak, P. Y., Leong, C. O. & Cheah, S. C. The role of Epstein-Barr virus in nasopharyngeal carcinoma. Front. Microbiol. 14, 1116143 (2023).","journal-title":"Front. Microbiol."},{"key":"1079_CR6","unstructured":"National Cancer Registry Department. Summary of the Malaysia National Cancer Registry report 2017-2021. Ministry of Health https:\/\/nci.moh.gov.my\/images\/pdf_folder\/SUMMARY-OF-MALAYSIA-NATIONAL-CANCER-REGISTRY-REPORT-2017-2021.pdf (2025)."},{"key":"1079_CR7","unstructured":"Singapore Cancer Registry. Singapore Cancer Registry annual report 2022. National Registry of Diseases Office https:\/\/www.nrdo.gov.sg\/publications\/cancer (2024)."},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","volume":"77","author":"KH Au","year":"2018","unstructured":"Au, K. H. et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral. Oncol. 77, 16\u201321 (2018).","journal-title":"Oral. Oncol."},{"key":"1079_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2017.02.029","volume":"77","author":"X Zou","year":"2017","unstructured":"Zou, X. et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur. J. Cancer 77, 117\u2013126 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1079_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205063","volume":"13","author":"C-H Liao","year":"2021","unstructured":"Liao, C.-H. et al. Quality of life as a mediator between cancer stage and long-term mortality in nasopharyngeal cancer patients treated with intensity-modulated radiotherapy. Cancers 13, 5063 (2021).","journal-title":"Cancers"},{"key":"1079_CR11","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.3747\/co.22.2323","volume":"22","author":"JS Hong","year":"2015","unstructured":"Hong, J. S., Tian, J., Han, Q. F. & Ni, Q. Y. Quality of life of nasopharyngeal cancer survivors in China. Curr. Oncol. 22, e142\u2013e147 (2015).","journal-title":"Curr. Oncol."},{"key":"1079_CR12","unstructured":"Hong Kong Cancer Registry. Nasopharyngeal cancer in 2022. Hong Kong Cancer Registry, Hospital Authority. https:\/\/www3.ha.org.hk\/cancereg\/pdf\/factsheet\/2022\/npc_2022.pdf (2022)."},{"key":"1079_CR13","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.ijrobp.2008.07.062","volume":"73","author":"YP Mao","year":"2009","unstructured":"Mao, Y. P. et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 73, 1326\u20131334 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1079_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.1895","volume":"8","author":"MB Alsavaf","year":"2025","unstructured":"Alsavaf, M. B. et al. Patient characteristics and treatment outcomes of nasopharyngeal carcinoma in nonendemic regions. JAMA Netw. Open 8, e251895 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1079_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard, P. et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 16, 645\u2013655 (2015).","journal-title":"Lancet Oncol."},{"key":"1079_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1055-9965.EPI-20-1702","volume":"30","author":"ET Chang","year":"2021","unstructured":"Chang, E. T., Ye, W., Zeng, Y. X. & Adami, H. O. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomark. Prev. 30, 1035\u20131047 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1079_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cncr.20372","volume":"101","author":"WH Jia","year":"2004","unstructured":"Jia, W. H. et al. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer 101, 363\u2013369 (2004).","journal-title":"Cancer"},{"key":"1079_CR18","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1002\/cncr.30643","volume":"123","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area. Cancer 123, 2716\u20132725 (2017).","journal-title":"Cancer"},{"key":"1079_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/aje\/kwq358","volume":"173","author":"WL Hsu","year":"2011","unstructured":"Hsu, W. L. et al. Familial tendency and risk of nasopharyngeal carcinoma in Taiwan: effects of covariates on risk. Am. J. Epidemiol. 173, 292\u2013299 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"1079_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archotol.132.1.82","volume":"132","author":"KS Loh","year":"2006","unstructured":"Loh, K. S., Goh, B. C., Lu, J., Hsieh, W. S. & Tan, L. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch. Otolaryngol. Head Neck Surg. 132, 82\u201385 (2006).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"1079_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10689-008-9213-9","volume":"8","author":"WT Ng","year":"2009","unstructured":"Ng, W. T. et al. Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. Fam. Cancer 8, 103\u2013108 (2009).","journal-title":"Fam. Cancer"},{"key":"1079_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10689-010-9397-7","volume":"10","author":"CW Choi","year":"2011","unstructured":"Choi, C. W. et al. An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. Fam. Cancer 10, 133\u2013139 (2011).","journal-title":"Fam. Cancer"},{"key":"1079_CR23","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1158\/0008-5472.CAN-04-4208","volume":"65","author":"J Friborg","year":"2005","unstructured":"Friborg, J. et al. Cancer susceptibility in nasopharyngeal carcinoma families \u2014 a population-based cohort study. Cancer Res. 65, 8567\u20138572 (2005).","journal-title":"Cancer Res."},{"key":"1079_CR24","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/jamaoto.2020.4197","volume":"146","author":"CW Noel","year":"2020","unstructured":"Noel, C. W. et al. Association of immigration status and Chinese and South Asian ethnicity with incidence of head and neck cancer. JAMA Otolaryngol. Head Neck Surg. 146, 1125\u20131135 (2020).","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"1079_CR25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ijc.34154","volume":"151","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Racial and ethnic disparities in nasopharyngeal cancer with an emphasis among Asian Americans. Int. J. Cancer 151, 1291\u20131303 (2022).","journal-title":"Int. J. Cancer"},{"key":"1079_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajhg.2009.07.007","volume":"85","author":"KP Tse","year":"2009","unstructured":"Tse, K. P. et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am. J. Hum. Genet. 85, 194\u2013203 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"1079_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ng.601","volume":"42","author":"JX Bei","year":"2010","unstructured":"Bei, J. X. et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat. Genet. 42, 599\u2013603 (2010).","journal-title":"Nat. Genet."},{"key":"1079_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003103","volume":"8","author":"M Tang","year":"2012","unstructured":"Tang, M. et al. The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. PLoS Genet. 8, e1003103 (2012).","journal-title":"PLoS Genet."},{"key":"1079_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/ijc.29035","volume":"136","author":"YM Chin","year":"2015","unstructured":"Chin, Y. M. et al. HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. Int. J. Cancer 136, 678\u2013687 (2015).","journal-title":"Int. J. Cancer"},{"key":"1079_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29570-4","volume":"13","author":"YQ He","year":"2022","unstructured":"He, Y. Q. et al. A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening. Nat. Commun. 13, 1966 (2022).","journal-title":"Nat. Commun."},{"key":"1079_CR31","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/jnci\/djac177","volume":"114","author":"TM Wang","year":"2022","unstructured":"Wang, T. M. et al. Whole-exome sequencing study of familial nasopharyngeal carcinoma and its implication for identifying high-risk individuals. J. Natl Cancer Inst. 114, 1689\u20131697 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100474","volume":"4","author":"M Xu","year":"2024","unstructured":"Xu, M. et al. Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: assessment of interaction and mediation. Cell Genom. 4, 100474 (2024).","journal-title":"Cell Genom."},{"key":"1079_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet. 51, 1131\u20131136 (2019).","journal-title":"Nat. Genet."},{"key":"1079_CR34","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1002\/ijc.32049","volume":"144","author":"KF Hui","year":"2019","unstructured":"Hui, K. F. et al. High risk Epstein-Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma. Int. J. Cancer 144, 3031\u20133042 (2019).","journal-title":"Int. J. Cancer"},{"key":"1079_CR35","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/jn\/nxz095","volume":"149","author":"D Barrett","year":"2019","unstructured":"Barrett, D. et al. Past and recent salted fish and preserved food intakes are weakly associated with nasopharyngeal carcinoma risk in adults in Southern China. J. Nutr. 149, 1596\u20131605 (2019).","journal-title":"J. Nutr."},{"key":"1079_CR36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.21037\/tcr-22-690","volume":"11","author":"H Feng","year":"2022","unstructured":"Feng, H. et al. Consumption of processed food and risk of nasopharyngeal carcinoma: a systematic review and meta-analysis. Transl. Cancer Res. 11, 872\u2013879 (2022).","journal-title":"Transl. Cancer Res."},{"key":"1079_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/bjc.1994.92","volume":"69","author":"YM Zheng","year":"1994","unstructured":"Zheng, Y. M. et al. Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu county, Guangxi, China. Br. J. Cancer 69, 508\u2013514 (1994).","journal-title":"Br. J. Cancer"},{"key":"1079_CR38","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/ijc.24293","volume":"124","author":"X Guo","year":"2009","unstructured":"Guo, X. et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of southern China. Int. J. Cancer 124, 2942\u20132947 (2009).","journal-title":"Int. J. Cancer"},{"key":"1079_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<228::AID-IJC11>3.0.CO;2-7","volume":"77","author":"RW Armstrong","year":"1998","unstructured":"Armstrong, R. W. et al. Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. Int. J. Cancer 77, 228\u2013235 (1998).","journal-title":"Int. J. Cancer"},{"key":"1079_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-446","volume":"10","author":"WH Jia","year":"2010","unstructured":"Jia, W. H. et al. Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China. BMC Cancer 10, 446 (2010).","journal-title":"BMC Cancer"},{"key":"1079_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-016-0174-3","volume":"36","author":"SK Yong","year":"2017","unstructured":"Yong, S. K. et al. Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: a case-control study. Chin. J. Cancer 36, 3 (2017).","journal-title":"Chin. J. Cancer"},{"key":"1079_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-021-00667-8","volume":"20","author":"ZM Mai","year":"2021","unstructured":"Mai, Z. M. et al. Dietary fiber intake from fresh and preserved food and risk of nasopharyngeal carcinoma: observational evidence from a Chinese population. Nutr. J. 20, 14 (2021).","journal-title":"Nutr. J."},{"key":"1079_CR43","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1002\/cncr.32458","volume":"125","author":"C Lin","year":"2019","unstructured":"Lin, C. et al. Chinese nonmedicinal herbal diet and risk of nasopharyngeal carcinoma: a population-based case-control study. Cancer 125, 4462\u20134470 (2019).","journal-title":"Cancer"},{"key":"1079_CR44","first-page":"589","volume":"23","author":"YT Liu","year":"2012","unstructured":"Liu, Y. T. et al. Greater intake of fruit and vegetables is associated with lower risk of nasopharyngeal carcinoma in Chinese adults: a case-control study. Cancer Causes Control. 23, 589\u2013599 (2012).","journal-title":"Cancer Causes Control."},{"key":"1079_CR45","first-page":"1157","volume":"24","author":"J Polesel","year":"2013","unstructured":"Polesel, J. et al. Consumption of fruit, vegetables, and other food groups and the risk of nasopharyngeal carcinoma. Cancer Causes Control. 24, 1157\u20131165 (2013).","journal-title":"Cancer Causes Control."},{"key":"1079_CR46","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cncr.22501","volume":"109","author":"JT Friborg","year":"2007","unstructured":"Friborg, J. T. et al. A prospective study of tobacco and alcohol use as risk factors for pharyngeal carcinomas in Singapore Chinese. Cancer 109, 1183\u20131191 (2007).","journal-title":"Cancer"},{"key":"1079_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/1055-9965.EPI-20-1244","volume":"30","author":"R Feng","year":"2021","unstructured":"Feng, R. et al. Intake of alcohol and tea and risk of nasopharyngeal carcinoma: a population-based case-control study in southern China. Cancer Epidemiol. Biomark. Prev. 30, 545\u2013553 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1079_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01635580802372633","volume":"61","author":"L Chen","year":"2009","unstructured":"Chen, L. et al. Alcohol consumption and the risk of nasopharyngeal carcinoma: a systematic review. Nutr. Cancer 61, 1\u201315 (2009).","journal-title":"Nutr. Cancer"},{"key":"1079_CR49","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1111\/acer.14184","volume":"43","author":"T Du","year":"2019","unstructured":"Du, T. et al. Association between alcohol consumption and risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of epidemiological studies. Alcohol. Clin. Exp. Res. 43, 2262\u20132273 (2019).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1079_CR50","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/ije\/dyab060","volume":"50","author":"JH Lin","year":"2021","unstructured":"Lin, J. H. et al. Smoking and nasopharyngeal cancer: individual data meta-analysis of six prospective studies on 334 935 men. Int. J. Epidemiol. 50, 975\u2013986 (2021).","journal-title":"Int. J. Epidemiol."},{"key":"1079_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/aje\/kws479","volume":"178","author":"WQ Xue","year":"2013","unstructured":"Xue, W. Q., Qin, H. D., Ruan, H. L., Shugart, Y. Y. & Jia, W. H. Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. Am. J. Epidemiol. 178, 325\u2013338 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"1079_CR52","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/aje\/kwx018","volume":"185","author":"ET Chang","year":"2017","unstructured":"Chang, E. T. et al. Active and passive smoking and risk of nasopharyngeal carcinoma: a population-based case-control study in southern China. Am. J. Epidemiol. 185, 1272\u20131280 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"1079_CR53","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cam4.2083","volume":"8","author":"T Hu","year":"2019","unstructured":"Hu, T. et al. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr virus: an analysis of a prospective study in southern China. Cancer Med. 8, 2561\u20132571 (2019).","journal-title":"Cancer Med."},{"key":"1079_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016582","volume":"7","author":"M Long","year":"2017","unstructured":"Long, M., Fu, Z., Li, P. & Nie, Z. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. BMJ Open 7, e016582 (2017).","journal-title":"BMJ Open"},{"key":"1079_CR55","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/cam4.2832","volume":"9","author":"WL Hsu","year":"2020","unstructured":"Hsu, W. L. et al. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: a mediation analysis. Cancer Med. 9, 1867\u20131876 (2020).","journal-title":"Cancer Med."},{"key":"1079_CR56","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jnci\/djs320","volume":"104","author":"FH Xu","year":"2012","unstructured":"Xu, F. H. et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J. Natl Cancer Inst. 104, 1396\u20131410 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR57","first-page":"913","volume":"26","author":"SH Xie","year":"2015","unstructured":"Xie, S. H., Yu, I. T., Tse, L. A., Au, J. S. & Lau, J. S. Tobacco smoking, family history, and the risk of nasopharyngeal carcinoma: a case-referent study in Hong Kong Chinese. Cancer Causes Control. 26, 913\u2013921 (2015).","journal-title":"Cancer Causes Control."},{"key":"1079_CR58","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/ijc.25696","volume":"129","author":"X Ji","year":"2011","unstructured":"Ji, X. et al. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int. J. Cancer 129, 724\u2013732 (2011).","journal-title":"Int. J. Cancer"},{"key":"1079_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-2035-x","volume":"15","author":"YQ He","year":"2015","unstructured":"He, Y. Q. et al. Household inhalants exposure and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China. BMC Cancer 15, 1022 (2015).","journal-title":"BMC Cancer"},{"key":"1079_CR60","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1002\/cncr.33536","volume":"127","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Occupational exposures and risk of nasopharyngeal carcinoma in a high-risk area: a population-based case-control study. Cancer 127, 2724\u20132735 (2021).","journal-title":"Cancer"},{"key":"1079_CR61","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/eurpub\/ckz239","volume":"30","author":"M E","year":"2020","unstructured":"E, M. et al. Wood dust exposure and risks of nasopharyngeal carcinoma: a meta-analysis. Eur. J. Public Health 30, 817\u2013822 (2020).","journal-title":"Eur. J. Public Health"},{"key":"1079_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2021.106455","volume":"151","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Residence characteristics and risk of nasopharyngeal carcinoma in southern China: a population-based case-control study. Env. Int. 151, 106455 (2021).","journal-title":"Env. Int."},{"key":"1079_CR63","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/ijerph17061824","volume":"17","author":"T Yang","year":"2020","unstructured":"Yang, T., Liu, Y., Zhao, W., Chen, Z. & Deng, J. Association of ambient air pollution with nasopharyngeal carcinoma incidence in ten large Chinese cities, 2006-2013. Int. J. Environ. Res. Public Health 17, 1824 (2020).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1079_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204568","volume":"13","author":"HC Fan","year":"2018","unstructured":"Fan, H. C. et al. Increased risk of incident nasopharyngeal carcinoma with exposure to air pollution. PLoS ONE\u00a013, e0204568 (2018).","journal-title":"PLoS ONE"},{"key":"1079_CR65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/jim-2019-001119","volume":"68","author":"HC Huang","year":"2020","unstructured":"Huang, H. C. et al. Association between coarse particulate matter (PM(10-2.5)) and nasopharyngeal carcinoma among Taiwanese men. J. Investig. Med. 68, 419\u2013424 (2020).","journal-title":"J. Investig. Med."},{"key":"1079_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110613","volume":"202","author":"B Chen","year":"2025","unstructured":"Chen, B. et al. Long-term trends in the burden of nasopharyngeal carcinoma in China: a comprehensive analysis from 1990 to 2021 and projections to 2030 based on the Global Burden of Disease Study 2021. Radiother. Oncol. 202, 110613 (2025).","journal-title":"Radiother. Oncol."},{"key":"1079_CR67","first-page":"1188","volume":"59","author":"YM Lo","year":"1999","unstructured":"Lo, Y. M. et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59, 1188\u20131191 (1999).","journal-title":"Cancer Res."},{"key":"1079_CR68","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/path.5249","volume":"247","author":"WKJ Lam","year":"2019","unstructured":"Lam, W. K. J., Chan, K. C. A. & Lo, Y. M. D. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J. Pathol. 247, 641\u2013649 (2019).","journal-title":"J. Pathol."},{"key":"1079_CR69","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","volume":"94","author":"ATC Chan","year":"2002","unstructured":"Chan, A. T. C. et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst. 94, 1614\u20131619 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR70","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin, J. C. et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 350, 2461\u20132470 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR71","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","volume":"24","author":"SF Leung","year":"2006","unstructured":"Leung, S. F. et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J. Clin. Oncol. 24, 5414\u20135418 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcv.2012.05.017","volume":"55","author":"SJ Chai","year":"2012","unstructured":"Chai, S. J. et al. Clinical significance of plasma Epstein-Barr virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma. J. Clin. Virol. 55, 34\u201339 (2012).","journal-title":"J. Clin. Virol."},{"key":"1079_CR73","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.18632\/oncotarget.14137","volume":"8","author":"VH Lee","year":"2017","unstructured":"Lee, V. H. et al. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget 8, 5292\u20135308 (2017).","journal-title":"Oncotarget"},{"key":"1079_CR74","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ijrobp.2006.05.064","volume":"66","author":"BB Ma","year":"2006","unstructured":"Ma, B. B. et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66, 714\u2013720 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1079_CR75","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1373\/clinchem.2005.054783","volume":"51","author":"KC Chan","year":"2005","unstructured":"Chan, K. C. et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin. Chem. 51, 2192\u20132195 (2005).","journal-title":"Clin. Chem."},{"key":"1079_CR76","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan, K. C. A. et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513\u2013522 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR77","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ijrobp.2004.07.702","volume":"61","author":"AW Lee","year":"2005","unstructured":"Lee, A. W. et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int. J. Radiat. Oncol. Biol. Phys. 61, 1107\u20131116 (2005).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1079_CR78","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200309","volume":"2","author":"KCA Chan","year":"2023","unstructured":"Chan, K. C. A. et al. Plasma Epstein-Barr virus DNA and risk of future nasopharyngeal cancer. NEJM Evid. 2, EVIDoa2200309 (2023).","journal-title":"NEJM Evid."},{"key":"1079_CR79","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/jnci\/djad012","volume":"115","author":"WKJ Lam","year":"2023","unstructured":"Lam, W. K. J. et al. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. J. Natl Cancer Inst. 115, 355\u2013364 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR80","first-page":"475","volume":"391","author":"J Kanakry","year":"2015","unstructured":"Kanakry, J. & Ambinder, R. The biology and clinical utility of EBV monitoring in blood. Curr. Top. Microbiol. Immunol. 391, 475\u2013499 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1079_CR81","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/cncr.28001","volume":"119","author":"KC Chan","year":"2013","unstructured":"Chan, K. C. et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 119, 1838\u20131844 (2013).","journal-title":"Cancer"},{"key":"1079_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11226-5","volume":"10","author":"WKJ Lam","year":"2019","unstructured":"Lam, W. K. J. et al. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nat. Commun. 10, 3256 (2019).","journal-title":"Nat. Commun."},{"key":"1079_CR83","first-page":"2028","volume":"63","author":"KC Chan","year":"2003","unstructured":"Chan, K. C. et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 63, 2028\u20132032 (2003).","journal-title":"Cancer Res."},{"key":"1079_CR84","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1056\/NEJMc1800433","volume":"378","author":"KCA Chan","year":"2018","unstructured":"Chan, K. C. A., Chu, S. W. I. & Lo, Y. M. D. Ambient temperature and screening for nasopharyngeal cancer. N. Engl. J. Med. 378, 962\u2013963 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158285","volume":"11","author":"HY Wang","year":"2016","unstructured":"Wang, H. Y. et al. Cancers screening in an asymptomatic population by using multiple tumour markers. PLoS ONE\u00a011, e0158285 (2016).","journal-title":"PLoS ONE"},{"key":"1079_CR86","doi-asserted-by":"publisher","first-page":"E5115","DOI":"10.1073\/pnas.1804184115","volume":"115","author":"WKJ Lam","year":"2018","unstructured":"Lam, W. K. J. et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 115, E5115\u2013E5124 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1079_CR87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2209852119","volume":"119","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Epigenetic analysis of cell-free DNA by fragmentomic profiling. Proc. Natl Acad. Sci. USA 119, e2209852119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1079_CR88","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/jvi.29.2.657-665.1979","volume":"29","author":"JE Shaw","year":"1979","unstructured":"Shaw, J. E., Levinger, L. F. & Carter, C. W. Jr. Nucleosomal structure of Epstein-Barr virus DNA in transformed cell lines. J. Virol. 29, 657\u2013665 (1979).","journal-title":"J. Virol."},{"issue":"Pt 9","key":"1079_CR89","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1099\/0022-1317-66-9-1931","volume":"66","author":"PJ Dyson","year":"1985","unstructured":"Dyson, P. J. & Farrell, P. J. Chromatin structure of Epstein-Barr virus. J. Gen. Virol. 66(Pt 9), 1931\u20131940 (1985).","journal-title":"J. Gen. Virol."},{"key":"1079_CR90","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.chom.2012.06.008","volume":"12","author":"A Arvey","year":"2012","unstructured":"Arvey, A. et al. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12, 233\u2013245 (2012).","journal-title":"Cell Host Microbe"},{"key":"1079_CR91","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/v5041042","volume":"5","author":"A Arvey","year":"2013","unstructured":"Arvey, A., Tempera, I. & Lieberman, P. M. Interpreting the Epstein-Barr virus (EBV) epigenome using high-throughput data. Viruses 5, 1042\u20131054 (2013).","journal-title":"Viruses"},{"key":"1079_CR92","doi-asserted-by":"publisher","first-page":"16286","DOI":"10.1073\/pnas.0407320101","volume":"101","author":"E Johannsen","year":"2004","unstructured":"Johannsen, E. et al. Proteins of purified Epstein-Barr virus. Proc. Natl Acad. Sci. USA 101, 16286\u201316291 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1079_CR93","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1101\/gr.083550.108","volume":"19","author":"AF Fernandez","year":"2009","unstructured":"Fernandez, A. F. et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 19, 438\u2013451 (2009).","journal-title":"Genome Res."},{"key":"1079_CR94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2014.01.003","volume":"26","author":"I Tempera","year":"2014","unstructured":"Tempera, I. & Lieberman, P. M. Epigenetic regulation of EBV persistence and oncogenesis. Semin. Cancer Biol. 26, 22\u201329 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"1079_CR95","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.coviro.2013.03.005","volume":"3","author":"A Woellmer","year":"2013","unstructured":"Woellmer, A. & Hammerschmidt, W. Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. Curr. Opin. Virol. 3, 260\u2013265 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"1079_CR96","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2025.02.002","volume":"43","author":"WKJ Lam","year":"2025","unstructured":"Lam, W. K. J. et al. Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma. Cancer Cell 43, 728\u2013739.e5 (2025).","journal-title":"Cancer Cell"},{"key":"1079_CR97","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le, Q. T. et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin. Cancer Res. 19, 2208\u20132215 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1079_CR98","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.oraloncology.2013.12.011","volume":"50","author":"TT Yip","year":"2014","unstructured":"Yip, T. T., Ngan, R. K., Fong, A. H. & Law, S. C. Application of circulating plasma\/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral. Oncol. 50, 527\u2013538 (2014).","journal-title":"Oral. Oncol."},{"key":"1079_CR99","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx007","volume":"109","author":"KY Kim","year":"2017","unstructured":"Kim, K. Y. et al. Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer. J. Natl Cancer Inst. 109, djx007 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR100","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ijc.2910360505","volume":"36","author":"Y Zeng","year":"1985","unstructured":"Zeng, Y. et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA\/VCA antibody-positive persons in Wuzhou city, China. Int. J. Cancer 36, 545\u2013547 (1985).","journal-title":"Int. J. Cancer"},{"key":"1079_CR101","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/sj.bjc.6603609","volume":"96","author":"MF Ji","year":"2007","unstructured":"Ji, M. F. et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br. J. Cancer 96, 623\u2013630 (2007).","journal-title":"Br. J. Cancer"},{"key":"1079_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019100","volume":"6","author":"SM Cao","year":"2011","unstructured":"Cao, S. M. et al. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS ONE\u00a06, e19100 (2011).","journal-title":"PLoS ONE"},{"key":"1079_CR103","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ijc.2910290204","volume":"29","author":"Y Zeng","year":"1982","unstructured":"Zeng, Y. et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou city, China. Int. J. Cancer 29, 139\u2013141 (1982).","journal-title":"Int. J. Cancer"},{"key":"1079_CR104","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/cas.13296","volume":"108","author":"JJ Yao","year":"2017","unstructured":"Yao, J. J. et al. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Cancer Sci. 108, 1640\u20131647 (2017).","journal-title":"Cancer Sci."},{"key":"1079_CR105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/aje\/kws404","volume":"177","author":"Z Liu","year":"2013","unstructured":"Liu, Z. et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in southern China. Am. J. Epidemiol. 177, 242\u2013250 (2013).","journal-title":"Am. J. Epidemiol."},{"key":"1079_CR106","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/annonc\/mdz231","volume":"30","author":"MF Ji","year":"2019","unstructured":"Ji, M. F. et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann. Oncol. 30, 1630\u20131637 (2019).","journal-title":"Ann. Oncol."},{"key":"1079_CR107","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.23.01296","volume":"43","author":"WJ Chen","year":"2025","unstructured":"Chen, W. J. et al. Impact of an Epstein-Barr virus serology-based screening program on nasopharyngeal carcinoma mortality: a cluster-randomized controlled trial. J. Clin. Oncol. 43, 22\u201331 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR108","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa2301496","volume":"389","author":"T Li","year":"2023","unstructured":"Li, T. et al. Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer. N. Engl. J. Med. 389, 808\u2013819 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR109","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41571-023-00827-1","volume":"21","author":"WKJ Lam","year":"2024","unstructured":"Lam, W. K. J. & Chan, A. T. C. Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver? Nat. Rev. Clin. Oncol. 21, 6\u20137 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1079_CR110","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01107-19","volume":"57","author":"Z Liu","year":"2019","unstructured":"Liu, Z. et al. Multilaboratory assessment of Epstein-Barr virus serologic assays: the case for standardization. J. Clin. Microbiol. 57, e01107-19 (2019).","journal-title":"J. Clin. Microbiol."},{"key":"1079_CR111","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1200\/JCO.22.01979","volume":"41","author":"PJ Lou","year":"2023","unstructured":"Lou, P. J. et al. Performance and operational feasibility of Epstein-Barr virus-based screening for detection of nasopharyngeal carcinoma: direct comparison of two alternative approaches. J. Clin. Oncol. 41, 4257\u20134266 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR112","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/clinchem\/hvaa027","volume":"66","author":"WKJ Lam","year":"2020","unstructured":"Lam, W. K. J. et al. Sequencing analysis of plasma Epstein-Barr virus DNA reveals nasopharyngeal carcinoma-associated single nucleotide variant profiles. Clin. Chem. 66, 598\u2013605 (2020).","journal-title":"Clin. Chem."},{"key":"1079_CR113","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1093\/hmg\/ddw200","volume":"25","author":"Q Cui","year":"2016","unstructured":"Cui, Q. et al. An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma. Hum. Mol. Genet. 25, 3626\u20133634 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"1079_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25402-z","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma. Nat. Commun. 12, 5189 (2021).","journal-title":"Nat. Commun."},{"key":"1079_CR115","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/ijc.33424","volume":"148","author":"GH Chen","year":"2021","unstructured":"Chen, G. H. et al. Prospective assessment of a nasopharyngeal carcinoma risk score in a population undergoing screening. Int. J. Cancer 148, 2398\u20132406 (2021).","journal-title":"Int. J. Cancer"},{"key":"1079_CR116","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/clinchem\/hvac032","volume":"68","author":"GH Chen","year":"2022","unstructured":"Chen, G. H. et al. Utility of Epstein-Barr virus DNA in nasopharynx swabs as a reflex test to triage seropositive individuals in nasopharyngeal carcinoma screening programs. Clin. Chem. 68, 953\u2013962 (2022).","journal-title":"Clin. Chem."},{"key":"1079_CR117","doi-asserted-by":"publisher","first-page":"e00077-20","DOI":"10.1128\/JCM.00077-20","volume":"58","author":"J Simon","year":"2020","unstructured":"Simon, J. et al. Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology. J. Clin. Microbiol. 58, e00077-20 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"1079_CR118","doi-asserted-by":"publisher","first-page":"dyae098","DOI":"10.1093\/ije\/dyae098","volume":"53","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Prospective evaluation of the relevance of Epstein-Barr virus antibodies for early detection of nasopharyngeal carcinoma in Chinese adults. Int. J. Epidemiol. 53, dyae098 (2024).","journal-title":"Int. J. Epidemiol."},{"key":"1079_CR119","first-page":"1288","volume":"27","author":"AD King","year":"2006","unstructured":"King, A. D. et al. Magnetic resonance imaging for the detection of nasopharyngeal carcinoma. AJNR Am. J. Neuroradiol. 27, 1288\u20131291 (2006).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1079_CR120","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1148\/radiol.10101241","volume":"258","author":"AD King","year":"2011","unstructured":"King, A. D. et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology 258, 531\u2013537 (2011).","journal-title":"Radiology"},{"key":"1079_CR121","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.3174\/ajnr.A4456","volume":"36","author":"AD King","year":"2015","unstructured":"King, A. D. et al. Detection of nasopharyngeal carcinoma by MR imaging: diagnostic accuracy of MRI compared with endoscopy and endoscopic biopsy based on long-term follow-up. AJNR Am. J. Neuroradiol. 36, 2380\u20132385 (2015).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1079_CR122","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdz106","volume":"30","author":"AD King","year":"2019","unstructured":"King, A. D. et al. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Ann. Oncol. 30, 977\u2013982 (2019).","journal-title":"Ann. Oncol."},{"key":"1079_CR123","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/cncr.33552","volume":"127","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma. Cancer 127, 3403\u20133412 (2021).","journal-title":"Cancer"},{"key":"1079_CR124","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/jnci\/djad260","volume":"116","author":"AD King","year":"2024","unstructured":"King, A. D. et al. Early detection of nasopharyngeal carcinoma: performance of a short contrast-free screening magnetic resonance imaging. J. Natl Cancer Inst. 116, 665\u2013672 (2024).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104862","volume":"110","author":"L Ke","year":"2020","unstructured":"Ke, L. et al. Development of a self-constrained 3D DenseNet model in automatic detection and segmentation of nasopharyngeal carcinoma using magnetic resonance images. Oral. Oncol. 110, 104862 (2020).","journal-title":"Oral. Oncol."},{"key":"1079_CR126","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1007\/s00330-020-07451-y","volume":"31","author":"LM Wong","year":"2021","unstructured":"Wong, L. M. et al. Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI. Eur. Radiol. 31, 3856\u20133863 (2021).","journal-title":"Eur. Radiol."},{"key":"1079_CR127","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/jnci\/djaa198","volume":"113","author":"JA Miller","year":"2021","unstructured":"Miller, J. A., Le, Q. T., Pinsky, B. A. & Wang, H. Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein-Barr virus polymerase chain reaction or serology in high-incidence populations worldwide. J. Natl Cancer Inst. 113, 852\u2013862 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"1079_CR128","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/1055-9965.EPI-23-1486","volume":"33","author":"JA Miller","year":"2024","unstructured":"Miller, J. A. et al. Optimization and local cost-effectiveness of nasopharyngeal carcinoma screening strategies in southern China: secondary analysis of the guangdong randomized trial. Cancer Epidemiol. Biomark. Prev. 33, 884\u2013895 (2024).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1079_CR129","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1158\/1055-9965.EPI-24-0576","volume":"33","author":"PE Clark","year":"2024","unstructured":"Clark, P. E., Taparra, K. & Miller, J. A. Identification of high-incidence populations in the United States for anti-Epstein-Barr virus serologic screening for nasopharyngeal carcinoma. Cancer Epidemiol. Biomark. Prev. 33, 1706\u20131716 (2024).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1079_CR130","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0140-6736(24)01608-8","volume":"404","author":"L Zhong","year":"2024","unstructured":"Zhong, L., Zhao, Q., Zeng, M. S. & Zhang, X. Prophylactic vaccines against Epstein-Barr virus. Lancet 404, 845 (2024).","journal-title":"Lancet"},{"key":"1079_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.677027","volume":"12","author":"C Sun","year":"2021","unstructured":"Sun, C., Chen, X. C., Kang, Y. F. & Zeng, M. S. The status and prospects of Epstein-Barr virus prophylactic vaccine development. Front. Immunol. 12, 677027 (2021).","journal-title":"Front. Immunol."},{"key":"1079_CR132","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","volume":"17","author":"WT Jackman","year":"1999","unstructured":"Jackman, W. T., Mann, K. A., Hoffmann, H. J. & Spaete, R. R. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17, 660\u2013668 (1999).","journal-title":"Vaccine"},{"issue":"Pt 8","key":"1079_CR133","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1099\/0022-1317-69-8-2093","volume":"69","author":"AJ Morgan","year":"1988","unstructured":"Morgan, A. J., Finerty, S., Lovgren, K., Scullion, F. T. & Morein, B. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J. Gen. Virol. 69(Pt 8), 2093\u20132096 (1988).","journal-title":"J. Gen. Virol."},{"key":"1079_CR134","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/0264-410X(94)90240-2","volume":"12","author":"S Finerty","year":"1994","unstructured":"Finerty, S. et al. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 12, 1180\u20131184 (1994).","journal-title":"Vaccine"},{"issue":"Pt 2","key":"1079_CR135","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1099\/0022-1317-73-2-449","volume":"73","author":"S Finerty","year":"1992","unstructured":"Finerty, S. et al. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J. Gen. Virol. 73(Pt 2), 449\u2013453 (1992).","journal-title":"J. Gen. Virol."},{"key":"1079_CR136","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1016\/j.vaccine.2015.10.024","volume":"33","author":"E Servat","year":"2015","unstructured":"Servat, E. et al. Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo. Vaccine 33, 6771\u20136777 (2015).","journal-title":"Vaccine"},{"key":"1079_CR137","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749\u20131753 (2007).","journal-title":"J. Infect. Dis."},{"key":"1079_CR138","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","volume":"88","author":"L Rees","year":"2009","unstructured":"Rees, L. et al. A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88, 1025\u20131029 (2009).","journal-title":"Transplantation"},{"key":"1079_CR139","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen, M. et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25, 4697\u20134705 (2007).","journal-title":"Vaccine"},{"key":"1079_CR140","first-page":"171","volume":"84","author":"SY Gu","year":"1995","unstructured":"Gu, S. Y. et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand. 84, 171\u2013177 (1995).","journal-title":"Dev. Biol. Stand."},{"key":"1079_CR141","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui, X. et al. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine 31, 3039\u20133045 (2013).","journal-title":"Vaccine"},{"key":"1079_CR142","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu, W. et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity 50, 1305\u20131316.e6 (2019).","journal-title":"Immunity"},{"key":"1079_CR143","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00705-024-06095-3","volume":"169","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. GB and gH\/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection. Arch. Virol. 169, 167 (2024).","journal-title":"Arch. Virol."},{"key":"1079_CR144","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui, X. et al. Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34, 4050\u20134055 (2016).","journal-title":"Vaccine"},{"key":"1079_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen, B. & Tolia, N. H. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6, 70 (2021).","journal-title":"NPJ Vaccines"},{"key":"1079_CR146","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"1079_CR147","doi-asserted-by":"publisher","first-page":"100658","DOI":"10.1016\/j.xcrm.2022.100658","volume":"3","author":"H Malhi","year":"2022","unstructured":"Malhi, H. et al. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge. Cell Rep. Med. 3, 100658 (2022).","journal-title":"Cell Rep. Med."},{"key":"1079_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf3685","volume":"14","author":"CJ Wei","year":"2022","unstructured":"Wei, C. J. et al. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. Sci. Transl. Med. 14, eabf3685 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1079_CR149","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","volume":"31","author":"C Sun","year":"2023","unstructured":"Sun, C. et al. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe 31, 1882\u20131897.e10 (2023).","journal-title":"Cell Host Microbe"},{"key":"1079_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00907-y","volume":"9","author":"KR Edwards","year":"2024","unstructured":"Edwards, K. R. et al. A gH\/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge. NPJ Vaccines 9, 120 (2024).","journal-title":"NPJ Vaccines"},{"key":"1079_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.84","volume":"47","author":"MS Kang","year":"2015","unstructured":"Kang, M. S. & Kieff, E. Epstein-Barr virus latent genes. Exp. Mol. Med. 47, e131 (2015).","journal-title":"Exp. Mol. Med."},{"key":"1079_CR152","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui, E. P. et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 73, 1676\u20131688 (2013).","journal-title":"Cancer Res."},{"key":"1079_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302116","volume":"10","author":"GX Zhao","year":"2023","unstructured":"Zhao, G. X. et al. mRNA-based vaccines targeting the T-cell epitope-rich domain of Epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice. Adv. Sci. 10, e2302116 (2023).","journal-title":"Adv. Sci."},{"key":"1079_CR154","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman, M. N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352, 2271\u20132284 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1079_CR155","first-page":"368","volume":"74","author":"WS Rubinstein","year":"2024","unstructured":"Rubinstein, W. S. et al. Cancer screening with multicancer detection tests: a translational science review. CA Cancer J. Clin. 74, 368\u2013382 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1079_CR156","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223\u2013238 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1079_CR157","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9601","volume":"369","author":"AM Lennon","year":"2020","unstructured":"Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369, eabb9601 (2020).","journal-title":"Science"},{"key":"1079_CR158","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926\u2013930 (2018).","journal-title":"Science"},{"key":"1079_CR159","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw3616","volume":"372","author":"YMD Lo","year":"2021","unstructured":"Lo, Y. M. D., Han, D. S. C., Jiang, P. & Chiu, R. W. K. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science 372, eaaw3616 (2021).","journal-title":"Science"},{"key":"1079_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100242","volume":"3","author":"AR Thierry","year":"2023","unstructured":"Thierry, A. R. Circulating DNA fragmentomics and cancer screening. Cell Genom. 3, 100242 (2023).","journal-title":"Cell Genom."},{"key":"1079_CR161","doi-asserted-by":"publisher","first-page":"E1317","DOI":"10.1073\/pnas.1500076112","volume":"112","author":"P Jiang","year":"2015","unstructured":"Jiang, P. et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl Acad. Sci. USA 112, E1317\u2013E1325 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1079_CR162","doi-asserted-by":"publisher","first-page":"E8159","DOI":"10.1073\/pnas.1615800113","volume":"113","author":"KC Chan","year":"2016","unstructured":"Chan, K. C. et al. Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. Proc. Natl Acad. Sci. USA 113, E8159\u2013E8168 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1079_CR163","doi-asserted-by":"publisher","first-page":"E10925","DOI":"10.1073\/pnas.1814616115","volume":"115","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 115, E10925\u2013E10933 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1079_CR164","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-19-0622","volume":"10","author":"P Jiang","year":"2020","unstructured":"Jiang, P. et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation. Cancer Discov. 10, 664\u2013673 (2020).","journal-title":"Cancer Discov."},{"key":"1079_CR165","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","volume":"24","author":"BD Nicholson","year":"2023","unstructured":"Nicholson, B. D. et al. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. Lancet Oncol. 24, 733\u2013743 (2023).","journal-title":"Lancet Oncol."},{"key":"1079_CR166","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 402, 1251\u20131260 (2023).","journal-title":"Lancet"},{"key":"1079_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO-24-01605","volume":"43","author":"PE Castle","year":"2025","unstructured":"Castle, P. E. & Han, P. K. J. On the nose: reducing nasopharyngeal cancer-related mortality using risk-based Epstein-Barr virus serology screening. J. Clin. Oncol. 43, 1\u20133 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1079_CR168","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/jhg.2009.49","volume":"54","author":"CC Ng","year":"2009","unstructured":"Ng, C. C. et al. A genome-wide association study identifies ITGA9 conferring risk of nasopharyngeal carcinoma. J. Hum. Genet. 54, 392\u2013397 (2009).","journal-title":"J. Hum. Genet."},{"key":"1079_CR169","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.ajhg.2023.06.003","volume":"110","author":"TM Wang","year":"2023","unstructured":"Wang, T. M. et al. High-throughput identification of regulatory elements and functional assays to uncover susceptibility genes for nasopharyngeal carcinoma. Am. J. Hum. Genet. 110, 1162\u20131176 (2023).","journal-title":"Am. J. Hum. Genet."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01079-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:03:36Z","timestamp":1765537416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":169,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01079-x","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"15 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.K.J.L. holds equity in Illumina. K.C.A.C. holds equity in DRA, Illumina, Insighta and Take2. B.B.Y.M., A.D.K., Y.M. and A.T.C.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}